Published in Br J Cancer on May 18, 2001
The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2011) 3.29
Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer (2007) 3.12
Association of leukocyte telomere length with breast cancer risk: nested case-control findings from the Shanghai Women's Health Study. Am J Epidemiol (2013) 2.34
Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst (2014) 1.96
Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. Hum Mol Genet (2015) 1.20
Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians. Cancer Res (2014) 1.04
Chromosome 9 arm-specific telomere length and breast cancer risk. Carcinogenesis (2009) 1.03
Telomere length in peripheral blood and breast cancer risk in a prospective case-cohort analysis: results from the Sister Study. Cancer Causes Control (2011) 1.02
Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation. Blood (2012) 1.01
Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol (2014) 1.00
Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know? Semin Oncol (2013) 0.99
Leukocyte telomere length, breast cancer risk in the offspring: the relations with father's age at birth. Mech Ageing Dev (2011) 0.94
The association of telomere length with colorectal cancer differs by the age of cancer onset. Clin Transl Gastroenterol (2014) 0.93
Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression. Blood (2007) 0.91
Telomere deficiencies on chromosomes 9p, 15p, 15q and Xp: potential biomarkers for breast cancer risk. Hum Mol Genet (2010) 0.88
Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Clin Cancer Res (2013) 0.87
Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus. Neoplasia (2004) 0.85
Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients. Breast Cancer Res Treat (2014) 0.84
Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status. PLoS One (2014) 0.83
The presence of telomere fusion in sporadic colon cancer independently of disease stage, TP53/KRAS mutation status, mean telomere length, and telomerase activity. Neoplasia (2014) 0.82
Potential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesis. Biol Res Nurs (2013) 0.81
The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget (2016) 0.78
Up-regulating telomerase and tumor suppressors: focusing on anti-aging interventions at the population level. Aging Dis (2013) 0.75
A retrospective examination of mean relative telomere length in the Tasmanian Familial Hematological Malignancies Study. Oncol Rep (2014) 0.75
Cognitive Effects of Chemotherapy and Cancer-Related Treatments in Older Adults. Am J Geriatr Psychiatry (2017) 0.75
A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res (1988) 77.80
Telomeres shorten during ageing of human fibroblasts. Nature (1990) 23.97
Telomere reduction in human colorectal carcinoma and with ageing. Nature (1990) 11.24
Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell (1999) 6.98
Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol (1998) 4.68
Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A (1994) 4.57
Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet (1998) 2.87
Progressive telomere shortening in aplastic anemia. Blood (1998) 2.10
Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1987) 1.81
Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood (1998) 1.77
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1997) 1.75
In vivo telomere dynamics of human hematopoietic stem cells. Proc Natl Acad Sci U S A (1997) 1.58
Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood (1997) 1.52
Rapid telomere shortening in children. Blood (1999) 1.35
Human ageing and telomeres. Ciba Found Symp (1997) 1.25
Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns. Br J Haematol (2000) 1.14
Changes of telomere length in children after hematopoietic stem cell transplantation. Bone Marrow Transplant (1998) 1.05
Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res (1999) 1.03
Telomere length changes in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant (1999) 1.00
Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2000) 0.97
Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear. J Clin Oncol (1998) 0.96
Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Hematother (1996) 0.96
Isolation of telomere junction fragments by anchored polymerase chain reaction. Proc Biol Sci (1992) 0.93
Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res (2000) 0.92
Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection. Blood (1999) 0.91
A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood (1998) 0.87
Measurement of telomere length in haematopoietic cells using in situ hybridization techniques. Biochem Soc Trans (2000) 0.85
Telomere shortening in leucocyte subsets of long-term survivors of allogeneic bone marrow transplantation. Br J Haematol (1999) 0.84
Breast cancer studies in The Netherlands. Lancet (1996) 0.84
Telomere shortening in leukemic cells is related to their genetic alterations but not replicative capability. Cancer Genet Cytogenet (1994) 0.82
High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age. J Natl Cancer Inst Monogr (1994) 0.79
High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience. J Hematother (1993) 0.78
Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma. Cancer Chemother Pharmacol (1996) 0.78
Mycobacterium ulcerans infection. Lancet (1999) 4.52
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther (2010) 3.42
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A (1994) 2.52
Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature (1988) 2.47
Neutral amino acid transport by membrane vesicles of Streptococcus cremoris is subject to regulation by internal pH. J Bacteriol (1987) 2.44
Elimination of uninformative variables for multivariate calibration. Anal Chem (1996) 2.30
Increased cancer risk after liver transplantation: a population-based study. J Hepatol (2001) 2.25
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (2000) 2.19
Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med (2001) 2.18
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover. Science (1996) 2.12
Sequence analysis and molecular characterization of the temperate lactococcal bacteriophage r1t. Mol Microbiol (1996) 2.10
Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res (1993) 1.99
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol (2001) 1.92
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol (2000) 1.89
Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology (2001) 1.84
Chromosomal damage in peripheral blood lymphocytes of patients treated for testicular cancer. Hum Genet (1990) 1.84
Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res (1993) 1.81
Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1987) 1.81
Transport of branched-chain amino acids in membrane vesicles of Streptococcus cremoris. J Bacteriol (1987) 1.72
hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene (1997) 1.67
Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol (1992) 1.62
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol (2000) 1.62
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer (2009) 1.53
Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer (1980) 1.52
Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol (2004) 1.52
Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis (2001) 1.52
Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer. Br J Surg (2001) 1.51
Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Trop Med Int Health (2001) 1.51
Mycobacterium ulcerans infection in Ashanti region, Ghana. Trans R Soc Trop Med Hyg (1990) 1.48
Neutrophil function capacity to express CD10 is decreased in patients with septic shock. Crit Care Med (1999) 1.44
Combination therapy with cisplatin: modulation of activity and tumour sensitivity. Clin Oncol (R Coll Radiol) (1992) 1.43
Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides. J Natl Cancer Inst (1995) 1.43
Syndrome X in testicular-cancer survivors. Lancet (2001) 1.43
Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) (2003) 1.43
Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. Clin Cancer Res (2000) 1.42
Rapid decreases in donor-specific cytotoxic T lymphocyte precursor frequencies and graft outcome after liver and lung transplantation. Transplantation (2001) 1.42
Large-amplitude spin dynamics driven by a THz pulse in resonance with an electromagnon. Science (2014) 1.41
5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Cancer (1995) 1.40
Endodermal sinus tumor of the ovary during pregnancy: a case report. Am J Obstet Gynecol (1991) 1.40
[Good results with liver resection for colorectal liver metastases]. Ned Tijdschr Geneeskd (1995) 1.40
Residual infrarenal aortic neck following endovascular and open aneurysm repair. Eur J Vasc Endovasc Surg (2012) 1.38
[Carboplatin in the treatment of ovarian carcinoma; as effective and less toxic in comparison with cisplatin]. Ned Tijdschr Geneeskd (1991) 1.38
Telomerase activity in needle biopsies from prostate cancer and benign prostates. Eur J Clin Invest (2000) 1.37
The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev (2000) 1.37
Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients. Antimicrob Agents Chemother (1981) 1.37
The clinical trail of TRAIL. Eur J Cancer (2006) 1.35
Review article: anthranoid laxatives and their potential carcinogenic effects. Aliment Pharmacol Ther (1999) 1.34
Acute and cumulative effects of carboplatin on renal function. Br J Cancer (1989) 1.33
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1990) 1.33
Nanoscale spin reversal by non-local angular momentum transfer following ultrafast laser excitation in ferrimagnetic GdFeCo. Nat Mater (2013) 1.31
Rolling-circle plasmids from Bacillus subtilis: complete nucleotide sequences and analyses of genes of pTA1015, pTA1040, pTA1050 and pTA1060, and comparisons with related plasmids from gram-positive bacteria. FEMS Microbiol Rev (1998) 1.28
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res (2001) 1.28
Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol (1998) 1.28
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer (1999) 1.27
Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ (2013) 1.27
Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer (1992) 1.25
Novel pyridinium surfactants for efficient, nontoxic in vitro gene delivery. Proc Natl Acad Sci U S A (1997) 1.23
Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol (1984) 1.23
Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther (2006) 1.22
Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res (1992) 1.21
Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst (1995) 1.21
Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res (1988) 1.21
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood (1995) 1.19
MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer (2007) 1.19
ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol (1999) 1.17
Familial testicular cancer in a single-centre population. Eur J Cancer (1999) 1.17
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res (1991) 1.16
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood (1994) 1.16
Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst (1989) 1.16
Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. J Cancer Res Clin Oncol (1989) 1.16
Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol (2006) 1.16
The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer (2008) 1.15
Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res (1992) 1.14
Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol (2001) 1.14
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis (2004) 1.13